A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

BackgroundAnlotinib may boost the efficacy of pancreatic cancer (PC) treatment if timely added to the GS regimen (Gemcitabine, Tegafur-gimeracil-oteracil potassium); however, no data has been published. This study evaluated the safety and efficacy of anlotinib in combination with the GS regimen(here...

Full description

Bibliographic Details
Main Authors: Gouling Zhan, Jianbing Hu, Shijian Da, Jie Weng, Chuanyi Zhou, Fang Wen, Songlian Liu, Fang Fang, Erdong Shen, Qiang Zhou, Pan Luo, Min Xu, Dahe Zhan, Yuqi Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Endocrinology
Subjects:
pancreatic cancer
anlotinib
GS regimen
efficacy
safety
overall survival
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1110624/full

Similar Items

Similar Items